PL2490712T3 - Sposób leczenia choroby Alzheimera przy zastosowaniu chaperonów farmakologicznych dla zwiększenia aktywności gangliozydaz - Google Patents
Sposób leczenia choroby Alzheimera przy zastosowaniu chaperonów farmakologicznych dla zwiększenia aktywności gangliozydazInfo
- Publication number
- PL2490712T3 PL2490712T3 PL10825421T PL10825421T PL2490712T3 PL 2490712 T3 PL2490712 T3 PL 2490712T3 PL 10825421 T PL10825421 T PL 10825421T PL 10825421 T PL10825421 T PL 10825421T PL 2490712 T3 PL2490712 T3 PL 2490712T3
- Authority
- PL
- Poland
- Prior art keywords
- gangliosidases
- disease
- activity
- increase
- treating alzheimer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Marine Sciences & Fisheries (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25279909P | 2009-10-19 | 2009-10-19 | |
| EP10825421.0A EP2490712B1 (en) | 2009-10-19 | 2010-10-12 | Method for treating alzheimer's disease using pharmacological chaperones to increase the activity of gangliosidases |
| PCT/US2010/052351 WO2011049787A1 (en) | 2009-10-19 | 2010-10-12 | Method for treating alzheimer's disease using pharmacological chaperones to increase the activity of gangliosidases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2490712T3 true PL2490712T3 (pl) | 2015-12-31 |
Family
ID=43900619
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL10825421T PL2490712T3 (pl) | 2009-10-19 | 2010-10-12 | Sposób leczenia choroby Alzheimera przy zastosowaniu chaperonów farmakologicznych dla zwiększenia aktywności gangliozydaz |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US9044437B2 (pl) |
| EP (2) | EP2957295B1 (pl) |
| JP (2) | JP6061677B2 (pl) |
| CA (1) | CA2778049C (pl) |
| DK (1) | DK2490712T3 (pl) |
| ES (2) | ES2549504T3 (pl) |
| HK (2) | HK1175400A1 (pl) |
| PL (1) | PL2490712T3 (pl) |
| PT (1) | PT2490712E (pl) |
| WO (1) | WO2011049787A1 (pl) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101880411B1 (ko) * | 2009-10-19 | 2018-07-19 | 아미쿠스 세라퓨틱스, 인코포레이티드 | 중추신경계의 퇴행성 질환을 예방 및/또는 치료하는 신규 조성물 |
| HUE037829T2 (hu) * | 2011-08-31 | 2018-09-28 | St Jude Childrens Res Hospital | Eljárások és készítmények lizoszomális exocitózis aktivitás mértékének detektálására és alkamazási eljárások |
| WO2013148103A1 (en) * | 2012-03-27 | 2013-10-03 | Amicus Therapeutics, Inc. | Novel compounds for preventing and/or treating lysosomal storage disorders and/or degenerative disorders of the central nervous system |
| US9675627B2 (en) * | 2014-04-14 | 2017-06-13 | Amicus Therapeutics, Inc. | Dosing regimens for treating and/or preventing cerebral amyloidoses |
| US10179128B2 (en) * | 2015-08-31 | 2019-01-15 | Amicus Therapeutics, Inc. | Regimens for treating and preventing lysosomal disorders and degenerative disorders of the central nervous system |
| US9994589B2 (en) | 2015-12-14 | 2018-06-12 | Amicus Therapeutics, Inc. | Compounds and methods for the treatment of alzheimer's disease and/or cerebral amyloid angiopathy |
| WO2019132004A1 (ja) * | 2017-12-28 | 2019-07-04 | 国立大学法人熊本大学 | アルツハイマー病予防剤又は治療剤、そのスクリーニング方法、及びアルツハイマー病予防用又は治療用組成物 |
| US20240043373A1 (en) * | 2020-08-28 | 2024-02-08 | The Regents Of The University Of California | Compositions and methods for treating amyloid-related conditions |
| WO2023288252A1 (en) * | 2021-07-13 | 2023-01-19 | Truebinding, Inc. | Methods of preventing protein aggregation |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5766846A (en) | 1992-07-10 | 1998-06-16 | Athena Neurosciences | Methods of screening for compounds which inhibit soluble β-amyloid peptide production |
| US6274597B1 (en) * | 1998-06-01 | 2001-08-14 | Mount Sinai School Of Medicine Of New York University | Method of enhancing lysosomal α-Galactosidase A |
| US20050031651A1 (en) * | 2002-12-24 | 2005-02-10 | Francine Gervais | Therapeutic formulations for the treatment of beta-amyloid related diseases |
| US20070066543A1 (en) * | 2003-05-22 | 2007-03-22 | The Hospital For Sick Children | Treatment of tay sachs or sandhoff diseases by enhancing hexosaminidase activity |
| JP2009509913A (ja) * | 2005-06-08 | 2009-03-12 | アミカス セラピューティックス インコーポレイテッド | リソソーム酵素をコードする遺伝子の変異に関連するｃｎｓ障害の治療 |
| ATE555788T1 (de) * | 2006-06-23 | 2012-05-15 | Amicus Therapeutics Inc | Verfahren zur behandlung neurologischer erkrankungen mittels verstärkung der beta - glucocerebrosidaseaktivität |
| JP2010525084A (ja) | 2007-04-26 | 2010-07-22 | アミカス セラピューティックス インコーポレイテッド | 薬理シャペロンを用いたリソソーム蓄積症治療のための投薬計画 |
| WO2011011181A1 (en) * | 2009-07-01 | 2011-01-27 | Amicus Therapeutics, Inc. | Pharmacological chaperones for the treatment of alzheimer's disease |
| US9675627B2 (en) * | 2014-04-14 | 2017-06-13 | Amicus Therapeutics, Inc. | Dosing regimens for treating and/or preventing cerebral amyloidoses |
-
2010
- 2010-10-12 PT PT108254210T patent/PT2490712E/pt unknown
- 2010-10-12 EP EP15173518.0A patent/EP2957295B1/en not_active Not-in-force
- 2010-10-12 ES ES10825421.0T patent/ES2549504T3/es active Active
- 2010-10-12 JP JP2012535238A patent/JP6061677B2/ja not_active Expired - Fee Related
- 2010-10-12 CA CA2778049A patent/CA2778049C/en not_active Expired - Fee Related
- 2010-10-12 EP EP10825421.0A patent/EP2490712B1/en not_active Not-in-force
- 2010-10-12 DK DK10825421.0T patent/DK2490712T3/en active
- 2010-10-12 WO PCT/US2010/052351 patent/WO2011049787A1/en active Application Filing
- 2010-10-12 US US13/501,586 patent/US9044437B2/en active Active
- 2010-10-12 PL PL10825421T patent/PL2490712T3/pl unknown
- 2010-10-12 ES ES15173518.0T patent/ES2646099T3/es active Active
-
2013
- 2013-02-27 HK HK13102468.4A patent/HK1175400A1/xx not_active IP Right Cessation
-
2015
- 2015-05-05 US US14/704,445 patent/US9931353B2/en active Active
- 2015-11-09 JP JP2015219607A patent/JP6204961B2/ja not_active Expired - Fee Related
-
2016
- 2016-03-24 HK HK16103501.8A patent/HK1215534A1/zh not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2011049787A1 (en) | 2011-04-28 |
| JP2013508371A (ja) | 2013-03-07 |
| CA2778049C (en) | 2018-12-04 |
| EP2490712B1 (en) | 2015-07-08 |
| JP6061677B2 (ja) | 2017-01-18 |
| US9044437B2 (en) | 2015-06-02 |
| PT2490712E (pt) | 2015-10-27 |
| JP6204961B2 (ja) | 2017-09-27 |
| CA2778049A1 (en) | 2011-04-28 |
| US20150374733A1 (en) | 2015-12-31 |
| EP2490712A4 (en) | 2013-06-12 |
| JP2016041741A (ja) | 2016-03-31 |
| US9931353B2 (en) | 2018-04-03 |
| ES2646099T3 (es) | 2017-12-12 |
| HK1215534A1 (zh) | 2016-09-02 |
| US20120309788A1 (en) | 2012-12-06 |
| EP2957295B1 (en) | 2017-08-02 |
| HK1175400A1 (en) | 2013-07-05 |
| EP2490712A1 (en) | 2012-08-29 |
| ES2549504T3 (es) | 2015-10-28 |
| EP2957295A1 (en) | 2015-12-23 |
| DK2490712T3 (en) | 2015-10-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL2490712T3 (pl) | Sposób leczenia choroby Alzheimera przy zastosowaniu chaperonów farmakologicznych dla zwiększenia aktywności gangliozydaz | |
| IL219412A0 (en) | New therapeutic approaches for treating alzheimer disease | |
| HK1163500A1 (en) | Pharmaceutical composition for the treatment of heart diseases | |
| EP2312945A4 (en) | PURE DERIVATIVES FOR THE TREATMENT OF MORBUS ALZHEIMER | |
| EP2485733A4 (en) | METHODS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | |
| IL216967A0 (en) | 17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl derivatives, method of production thereof and use thereof for the treatment of diseases | |
| GB2496801B (en) | A method of treating alzheimer's disease | |
| HK1176870A1 (zh) | 疾病的治療方法 | |
| GB0904427D0 (en) | Treatment of diseases related to hyperactivity of the complement system | |
| EP2398789A4 (en) | SPIROPYRROLIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | |
| PL3318881T3 (pl) | Sposób monitorowania choroby gauchera | |
| EP2391379A4 (en) | COMPOUNDS AND METHOD FOR THE TREATMENT OF MORBUS ALZHEIMER | |
| ZA201108496B (en) | System for treatment of biomass to facilitate the production of ethanol | |
| EP2496080A4 (en) | METHOD FOR THE TREATMENT OF MORBUS PARKINSON | |
| GB0909575D0 (en) | Method of screening for agents to treat alzheimer's disease | |
| GB0816956D0 (en) | Method of screening for agents to treat alzheimer's disease | |
| GB0915893D0 (en) | Method of screening for agents to treat Alzheimer's Disease | |
| GB0812780D0 (en) | Method of screening for agents to treat alzheimer's disease | |
| GB0812779D0 (en) | Method of screening for agents to treat alzheimer's disease |